With Covid sales de­clin­ing, Pfiz­er ze­roes in on M&A and on­col­o­gy

Pfiz­er’s first-quar­ter rev­enue tum­bled, as ex­pect­ed, due to dwin­dling sales of its Covid-19 prod­ucts, yet ex­ec­u­tives sought to re­in­force the com­pa­ny’s re­newed fo­cus on can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER